Navigation Links
IDM Pharma Announces Presentations at 44th American Society of Clinical Oncology Annual Meeting
Date:5/16/2008

IRVINE, Calif., May 16 /PRNewswire-FirstCall/ -- IDM Pharma, Inc. (Nasdaq: IDMI) today announced that clinical data presentations evaluating the Company's lead product candidates will be made at the upcoming 44th American Society of Clinical Oncology (ASCO) annual meeting. Data presented at the meeting will support improved survival for patients with metastatic osteosarcoma treated with L-MTP-PE, as well as patients with non-small lung cancer treated with IDM-2101.

Presentation highlights are as follows:

L-MTP-PE

"Addition of Muramyl Tripeptide to Chemotherapy for Patients with Newly

Diagnosed Metastatic Osteosarcoma: a Report from the Children's Oncology

Group"

Presenter: Alexander J Chou, MD, Department of Pediatrics, Memorial

Sloan-Kettering Cancer Center

Date/Time: Poster presentation, Sunday, June 1, 2008, 2 - 6 p.m., S Hall

A1; poster discussion period, 4:45 - 6 p.m., S504

Abstract Number: 10018

Poster Number: 52B

IDM-2101

"Induction of immune responses and clinical activity in a Phase 2 trial of

IDM-2101, a 10-epitope CTL vaccine, in metastatic NSCLC patients"

Presenter: Minal Barve, MD, practice director, Mary Crowley Cancer

Research Center

Date/Time: Sunday, June 1, 2008, 2 - 6 p.m., S Hall A1

Abstract Number: 8057

Poster Number: 43D

The 2008 ASCO annual meeting abstracts are currently available at http://www.asco.org.

About IDM Pharma

IDM Pharma is focused on the development of innovative cancer products that either destroy cancer cells by activating the immune system or prevent tumor recurrence by triggering a specific adaptive immune response. IDM Pharma is dedicated to maximizing the full therapeutic and commercial potential of each of its innovative products to address the needs of patients and the physicians who treat these patients.

For more information about the company and its products, visit http://www.idm-pharma.com.

Forward-Looking Statements

The presentations described in this press release will include forward- looking statements that reflect management's current views of future events regarding the development and characteristics of the Company's drug candidates L-MTP-PE and IDM-2101, including the Company's plans to address the remaining questions with respect to the Marketing Authorization Application (MAA) for L- MTP-PE during the clock-stop granted by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency, and the expected timing of a final opinion from the CHMP and of a final regulatory decision regarding the MAA in the European Union, as well as the Company's plans to collect, analyze and submit additional Phase 3 data in an amended New Drug Application (NDA) for L-MTP-PE, including the expected timing for such amended NDA, and to respond to other matters raised by the Food and Drug Administration (FDA), the potential for IDM-2101 as a treatment for NSCLC and plans to evaluate strategic alternatives. Actual results may differ materially from the forward- looking statements due to a number of important factors, including, but not limited to, whether the Company will be able to respond to the remaining issues with regard to the MAA, including verification of data quality and chemistry, manufacturing and controls (CMC) items, to the satisfaction of the CHMP, whether the CHMP will ask the Company for further information at or following the June 2008 meeting to address remaining issues with regard to the MAA, which would delay the timing of a final opinion from the CHMP, whether the final opinion of the CHMP will be consistent with the non-binding opinion of the CHMP, whether the European Commission will follow the final opinion of the CHMP once issued, whether the timing for the final opinion of the CHMP and the regulatory decision in Europe will occur as expected by the Company, the possibility that additional data from the Phase 3 clinical trial of L-MTP-PE and other information in any amendment to the NDA for L-MTP-PE submitted by the Company may not provide adequate support for regulatory approval of L-MTP- PE in the United States within the timeframe expected by the Company, if at all, whether the Company will be able to manufacture and commercialize L-MTP- PE even if it is approved by regulatory authorities, whether the Company will be able to complete any potential strategic transaction on terms acceptable to the Company's stockholders, and whether the cash resources of the Company will be sufficient to fund operations as planned. These and other risks affecting the Company and its drug development programs, intellectual property rights, personnel and business are more fully discussed in the Company's Quarterly Report on Form 10-Q filed with the SEC for the quarter ended March 31, 2008 and other periodic reports filed with the SEC. The Company expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.


'/>"/>
SOURCE IDM Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Jazz Pharmaceuticals to Present at Investor Conferences
2. Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008
3. Carlos A. Parra Joins Alexza Pharmaceuticals as Vice President, Quality
4. Pharmasset Reports Financial Results for Quarter Ended March 31, 2008
5. Wyeths Pristiq, a New Treatment for Major Depressive Disorder in Adults, Now Available in U.S. Pharmacies
6. Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results
7. 11 Pharmaceutical Titans Headline Chemistry Outsourcing Conference Program in September in New Jersey
8. AMDL Subsidiary Donates Pharmaceuticals in China Earthquake Relief Effort
9. Alseres Pharmaceuticals, Inc. Reports First Quarter 2008 Operational and Financial Results
10. Pharmacyclics Files Schedule 14D-9 Statement with Securities and Exchange Commission
11. Medsn to Become Indegene Pharmaceutical Solutions, Inc.: Change Signifies the Success of Its Innovative Global Services Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... ... On June 10-11, 2016, A Forever Recovery, a holistic treatment center for ... Table in Battle Creek, MI, where the rehabilitation facility is located. This annual celebration ... world’s leading providers of cereal and other breakfast foods. Its residents often refer to ...
(Date:6/26/2016)... Orion, Clarkston, Michigan (PRWEB) , ... June 26, ... ... with respect to fertility once they have been diagnosed with endometriosis. These women ... intercourse but they also require a comprehensive approach that can help for preservation ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users ... - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 ... Pro X . Simply select a ProHand generator and drag it above media or ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and ... their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took ... the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive ...
(Date:6/24/2016)... ... 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. ... the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has ... , Sickle Cell Disease (SCD) is a disorder of the red blood cells, which ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Va. , June 24, 2016 The ... set of recommendations that would allow biopharmaceutical ... (HCEI) with entities that make formulary and coverage decisions, ... the "value" of new medicines. The recommendations ... does not appear on the drug label, a prohibition ...
(Date:6/24/2016)... June 24, 2016 According to ... Type (Standard Pen Needles, Safety Pen Needles), Needle Length ... Growth Hormone), Mode of Purchase (Retail, Non-Retail) - Trends ... report studies the market for the forecast period of ... USD 2.81 Billion by 2021 from USD 1.65 Billion ...
(Date:6/23/2016)... , June 23, 2016  MedSource announced today ... its e-clinical software solution of choice.  This latest ... possible value to their clients by offering a ... preferred relationship establishes nowEDC as the EDC platform ... MedSource,s full-service clients.  "nowEDC has long been a ...
Breaking Medicine Technology: